LG Chem said that it has signed a local joint sales contract with Kyowa Kirin Korea for Nesp and Regpara, its chronic kidney disease (CKD) treatments.

Under the accord, LG Chem will operate at the clinic and hospital level, while Kyowa Kirin Korea will operate at the general hospital level.

LG Chem plans to present new treatment options for CKD to medical staff by packaging the two Kyowa Kirin products with its existing products, such as its first-generation hematopoietic agent Espogen and hyperkalemia treatment Nestykal.

“We will continue to offer various treatment options with customer value as our top priority,” an LG Chem official said. “We will do our best to expand the market as soon as possible based on a strong nationwide sales network and long business experience in the kidney disease area.”

An official from Kyowa Kirin also said, “We expect the joint sales partnership will further raise the brand awareness of Nesp and Legpara in hospitals, clinics, and small and medium-sized hospitals.”

Nesp Prefilled Syringe (Ingredient: Darbepoetin alfa) is a long-acting hematopoietic agent used to treat anemia in CKD patients and used on hemodialysis and peritoneal dialysis patients and CKD patients before dialysis.

Regpara is a product that obtained U.S. Food and Drug Administration (FDA) approval in 2004 as a treatment for secondary hyperparathyroidism in CKD patients.